Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00272311
Status:
COMPLETED
Last Update Posted:
2019-02-27
First Post:
2006-01-03
Brief Title:
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
Sponsor:
Florida Atlantic University
Organization:
Florida Atlantic University
Study Overview
Official Title:
A Randomized Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention Patients With Metabolic Syndrome
Status:
COMPLETED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PAD
Brief Summary:
The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients at risk of a first heart attack
Detailed Description:
Aspirin reduces risks of heart attacks strokes and deaths from cardiovascular causes in patients who have survived a prior event as well as during an acute heart attack Aspirin also prevents a first heart attack
Low dose aspirin is sufficient to achieve complete inhibition of platelet aggregability or stickiness and this is the mechanism whereby aspirin prevents formation of blood clots
Our research is designed to explore whether higher doses of aspirin provide additional benefits on markers of atherosclerosis
Low dose aspirin is sufficient to achieve complete inhibition of platelet aggregability or stickiness and this is the mechanism whereby aspirin prevents formation of blood clots
Our research is designed to explore whether higher doses of aspirin provide additional benefits on markers of atherosclerosis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None